Steven D. Reich

3.0k total citations
73 papers, 2.3k citations indexed

About

Steven D. Reich is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Steven D. Reich has authored 73 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Molecular Biology, 27 papers in Oncology and 17 papers in Hematology. Recurrent topics in Steven D. Reich's work include Cancer Treatment and Pharmacology (12 papers), Ubiquitin and proteasome pathways (11 papers) and Multiple Myeloma Research and Treatments (10 papers). Steven D. Reich is often cited by papers focused on Cancer Treatment and Pharmacology (12 papers), Ubiquitin and proteasome pathways (11 papers) and Multiple Myeloma Research and Treatments (10 papers). Steven D. Reich collaborates with scholars based in United States, Australia and Canada. Steven D. Reich's co-authors include Heidi Steinfeldt, George Wilding, Yazdi K. Pithavala, Roy S. Herbst, Hope S. Rugo, John W. Park, Glenn Liu, Merrill S. Kies, James L. Freddo and Mohit Trikha and has published in prestigious journals such as Journal of the American Chemical Society, Journal of Clinical Oncology and Blood.

In The Last Decade

Steven D. Reich

72 papers receiving 2.2k citations

Peers

Steven D. Reich
Dona Alberti United States
Ralf A. Hilger Germany
R. Osieka Germany
Robert J. Belt United States
Gregory D. Ayers United States
David Lebwohl United States
Donald Thornton United States
Paul Noordhuis Netherlands
Vicki Goodman United States
Roger Keresztes United States
Dona Alberti United States
Steven D. Reich
Citations per year, relative to Steven D. Reich Steven D. Reich (= 1×) peers Dona Alberti

Countries citing papers authored by Steven D. Reich

Since Specialization
Citations

This map shows the geographic impact of Steven D. Reich's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steven D. Reich with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steven D. Reich more than expected).

Fields of papers citing papers by Steven D. Reich

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steven D. Reich. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steven D. Reich. The network helps show where Steven D. Reich may publish in the future.

Co-authorship network of co-authors of Steven D. Reich

This figure shows the co-authorship network connecting the top 25 collaborators of Steven D. Reich. A scholar is included among the top collaborators of Steven D. Reich based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steven D. Reich. Steven D. Reich is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Shapiro, Geoffrey I., Ulka N. Vaishampayan, Patricia LoRusso, et al.. (2017). First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors. Investigational New Drugs. 35(3). 315–323. 32 indexed citations
3.
Spencer, Andrew, Simon J. Harrison, Jeffrey A. Zonder, et al.. (2017). A phase 1 clinical trial evaluating marizomib, pomalidomide and low‐dose dexamethasone in relapsed and refractory multiple myeloma (NPI‐0052‐107): final study results. British Journal of Haematology. 180(1). 41–51. 60 indexed citations
4.
Freyman, Amy, Steven D. Reich, Donghua Yin, et al.. (2016). Evaluating imbalances of adverse events during biosimilar development. mAbs. 8(5). 861–866. 2 indexed citations
5.
Yin, Donghua, Kerry Barker, Ruifeng Li, et al.. (2014). A randomized phase 1 pharmacokinetic trial comparing the potential biosimilarPF‐05280014 with trastuzumab in healthy volunteers (REFLECTIONS B327‐01). British Journal of Clinical Pharmacology. 78(6). 1281–1290. 60 indexed citations
6.
Reich, Steven D. & Robert Rosenbaum. (2013). The impact of short term synaptic depression and stochastic vesicle dynamics on neuronal variability. Journal of Computational Neuroscience. 35(1). 39–53. 9 indexed citations
7.
Gaba, Ron C., Ahmad Parvinian, Steven D. Reich, et al.. (2012). Splenic artery embolization: a single center review of safety, efficacy, and clinical outcomes. Diagnostic and Interventional Radiology. 19(1). 49–55. 19 indexed citations
8.
Lin, Jianqing, Marianna Zahurak, Tomasz M. Beer, et al.. (2011). A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-naïve prostate cancer. Urologic Oncology Seminars and Original Investigations. 31(5). 581–588. 53 indexed citations
9.
Giles, Francis J., William Bellamy, Zeev Estrov, et al.. (2005). The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Leukemia Research. 30(7). 801–811. 38 indexed citations
10.
Robert, Francisco, Chris R. Garrett, William R. Dinwoodie, et al.. (2004). Results of 2 phase I studies of intravenous (iv) pelitrexol (AG2037), a glycinamide ribonucleotide formyltransferase (GARFT) inhibitor, in patients (pts) with solid tumors. Journal of Clinical Oncology. 22(14_suppl). 3075–3075. 3 indexed citations
11.
Heald, Peter, et al.. (2003). Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial. Journal of the American Academy of Dermatology. 49(5). 801–815. 94 indexed citations
12.
Rizvi, Naiyer A., Michael Hawkins, Peter D. Eisenberg, Richard C. Yocum, & Steven D. Reich. (2001). Placebo-Controlled Trial of Bexarotene, a Retinoid X Receptor Agonist, as Maintenance Therapy for Patients Treated with Chemotherapy for Advanced Non–Small-Cell Lung Cancer. Clinical Lung Cancer. 2(3). 210–215. 22 indexed citations
13.
Khuri, Fadlo R., James R. Rigas, Robert A. Figlin, et al.. (2001). Multi-Institutional Phase I/II Trial of Oral Bexarotene in Combination With Cisplatin and Vinorelbine in Previously Untreated Patients With Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 19(10). 2626–2637. 107 indexed citations
14.
Persico, Antonio M., Steven D. Reich, Jack E. Henningfield, Michael J. Kuhar, & George R. Uhl. (1998). Parkinsonian patients report blunted subjective effects of methylphenidate.. Experimental and Clinical Psychopharmacology. 6(1). 54–63. 7 indexed citations
15.
Kirkwood, John M., Marc S. Ernstoff, Yuichi Nishida, et al.. (1990). In vivo biological response to recombinant interferon-gamma during a phase I dose-response trial in patients with metastatic melanoma.. Journal of Clinical Oncology. 8(6). 1070–1082. 16 indexed citations
16.
Welander, Charles E., Howard D. Homesley, Steven D. Reich, & Elizabeth Levin. (1988). A Phase II Study of the Efficacy of Recombinant Interferon Gamma in Relapsing Ovarian Adenocarcinoma. American Journal of Clinical Oncology. 11(4). 465–469. 30 indexed citations
17.
Ernstoff, Marc S., Carol A. Davis, Steven D. Reich, et al.. (1987). A randomized phase I/II study of continuous versus intermittent intravenous interferon gamma in patients with metastatic melanoma.. Journal of Clinical Oncology. 5(11). 1804–1810. 42 indexed citations
18.
López, José A., et al.. (1985). Clinical pharmacology of intraperitoneal cisplatin. Gynecologic Oncology. 20(1). 1–9. 51 indexed citations
19.
Egorin, Merrill J., et al.. (1983). Murine metabolism and disposition of iron:adriamycin complexes.. PubMed. 43(7). 3253–62. 12 indexed citations
20.
Solomon, Harvey M., et al.. (1971). INTERACTIONS BETWEEN DIGITOXIN AND OTHER DRUGS IN VITRO AND IN VIVO. Annals of the New York Academy of Sciences. 179(1). 362–369. 53 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Dona Alberti Breakdown of academic impact, for papers by Ralf A. Hilger Breakdown of academic impact, for papers by R. Osieka Breakdown of academic impact, for papers by Robert J. Belt Breakdown of academic impact, for papers by Gregory D. Ayers Breakdown of academic impact, for papers by David Lebwohl Breakdown of academic impact, for papers by Donald Thornton Breakdown of academic impact, for papers by Paul Noordhuis Breakdown of academic impact, for papers by Vicki Goodman Breakdown of academic impact, for papers by Roger Keresztes
Rankless by CCL
2026